Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | FURIN | P09958 | 2/20 | 0.51 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 14/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904521 | 0.97 | EGFR (0.54) | EGFRFURINPCSK6GRIN2DGRIN3B | |
| SCHEMBL29405957 | 0.90 | BACE1 (0.53) | BACE1BACE2CTSD | |
| SCHEMBL30343041 | 0.90 | CCNA2 (0.57) | NPY1RNPY2RNPY4R | |
| SCHEMBL30863949 | 0.89 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL30883804 | 0.88 | FURIN (0.52) | EGFRFURINPCSK6GRIN2DGRIN3B | |
| SCHEMBL29518464 | 0.88 | VIPR2 (0.54) | BACE1 | |
| SCHEMBL30262160 | 0.88 | BACE1 (0.56) | BACE1BACE2CTSD | |
| SCHEMBL29963530 | 0.87 | BACE1 (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29453331 | 0.87 | BACE1 (0.52) | BACE1BACE2CTSD | |
| SCHEMBL29414635 | 0.86 | BACE1 (0.58) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525985-A2 | COMPOSITIONS AND METHODS FOR TREATING A CARDIAC DISEASE | The Children's Medical Center Corporation (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250064983-A1 | COMPOSITIONS AND METHODS FOR TREATING A CARDIAC DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-02-27 | — | — | US | disclosed |
| CN-118001408-B | Application of aquaporin 9 phosphorylation inhibitor | 北京大学 | 2024-06-25 | — | — | CN | disclosed |
| JP-2024081764-A | Compositions and methods for treating or preventing catecholaminergic polymorphic ventricular tachycardia | ザ チルドレンズ メディカル センター コーポレーション | 2024-06-18 | — | — | JP | disclosed |
| US-11992493-B1 | Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity | Sun, Liangdan (CN) | 2024-05-28 | — | — | US | disclosed |
| CN-118001408-A | Application of aquaporin 9 phosphorylation inhibitor | 北京大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148746-A1 | USE OF COMPOUND OR PHARMACEUTICAL DERIVATIVE THEREOF IN INHIBITING CAMK2G PROTEIN ACTIVITY | SUN, LIANGDAN (CN) | 2024-05-09 | — | — | US | disclosed |
| EP-4360636-A1 | ALCAFTADINE FOR INHIBITING CAMK2G PROTEIN ACTIVITY | Sun, Liangdan (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-117919255-A | Use of compounds or pharmaceutically acceptable derivatives thereof for inhibiting CaMK2 gamma protein activity | 孙良丹 | 2024-04-26 | — | — | CN | disclosed |
| US-20240026458-A1 | Method for Determining Sensitivity to an Antineoplastic Agent | Université Libre de Bruxelles (BE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023224927-A2 | COMPOSITIONS AND METHODS FOR TREATING A CARDIAC DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4182479-A1 | METHOD FOR DETERMINING SENSITIVITY TO AN ANTINEOPLASTIC AGENT | Université Libre de Bruxelles (BE) | 2023-05-24 | — | — | EP | disclosed |
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148746-A1 | USE OF COMPOUND OR PHARMACEUTICAL DERIVATIVE THEREOF IN INHIBITING CAMK2G PROTEIN ACTIVITY | CAMK2G, CAMK1G, CAMK2A | EGFR 2213/4885FURIN 4689/4885PCSK6 3319/4885 |
| US-11992493-B1 | Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity | CAMK2G, CAMK1G, CAMK2A | EGFR 2213/4885FURIN 4689/4885PCSK6 3319/4885 |
| US-20250064983-A1 | COMPOSITIONS AND METHODS FOR TREATING A CARDIAC DISEASE | PNCK, CAMK2G, CAMK2B | EGFR 1932/4885FURIN 2001/4885PCSK6 1023/4885 |
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | EGFR 1338/4885FURIN 4788/4885PCSK6 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.